Oryzon Genomics S.A. (BME:ORY)
Spain
· Delayed Price · Currency is EUR 2.790
-0.022 (-0.78%)
Apr 28, 2026, 5:35 PM CET
Oryzon Genomics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 10.93 | 7.36 | 14.19 | 15.7 | 10.62 | Upgrade
|
| Revenue Growth (YoY) | 48.59% | -48.15% | -9.60% | 47.88% | 11.49% | Upgrade
|
| Cost of Revenue | 0.28 | 0.3 | 0.24 | 0.46 | 0.75 | Upgrade
|
| Gross Profit | 10.65 | 7.06 | 13.95 | 15.23 | 9.87 | Upgrade
|
| Selling, General & Admin | 3.79 | 3.55 | 3.61 | 3.57 | 3.67 | Upgrade
|
| Other Operating Expenses | 12.44 | 7.86 | 14.75 | 17 | 13.07 | Upgrade
|
| Operating Expenses | 16.36 | 11.56 | 18.51 | 20.73 | 16.88 | Upgrade
|
| Operating Income | -5.71 | -4.5 | -4.56 | -5.5 | -7.01 | Upgrade
|
| Interest Expense | -0 | -0 | -1.89 | -1.12 | -0.46 | Upgrade
|
| Interest & Investment Income | 0.71 | 0.2 | 0.03 | 0.01 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.05 | -0.09 | 0.1 | 0.24 | 0.28 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.65 | -1.17 | 0.2 | -0.2 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -5.6 | -5.56 | -6.12 | -6.56 | -7.18 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0 | Upgrade
|
| Asset Writedown | -0 | - | - | - | - | Upgrade
|
| Other Unusual Items | 0.01 | 0.08 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Pretax Income | -5.6 | -5.48 | -6.1 | -6.56 | -7.18 | Upgrade
|
| Income Tax Expense | -2.99 | -1.91 | -2.75 | -2.33 | -2.49 | Upgrade
|
| Net Income | -2.61 | -3.58 | -3.35 | -4.23 | -4.69 | Upgrade
|
| Net Income to Common | -2.61 | -3.58 | -3.35 | -4.23 | -4.69 | Upgrade
|
| Shares Outstanding (Basic) | 78 | 65 | 61 | 55 | 53 | Upgrade
|
| Shares Outstanding (Diluted) | 78 | 65 | 61 | 55 | 53 | Upgrade
|
| Shares Change (YoY) | 19.72% | 6.35% | 10.10% | 4.80% | - | Upgrade
|
| EPS (Basic) | -0.03 | -0.06 | -0.06 | -0.08 | -0.09 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.06 | -0.06 | -0.08 | -0.09 | Upgrade
|
| Free Cash Flow | -2.42 | -5.79 | -0.57 | -1.92 | -3.8 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.09 | -0.01 | -0.04 | -0.07 | Upgrade
|
| Gross Margin | 97.42% | 95.89% | 98.28% | 97.04% | 92.97% | Upgrade
|
| Operating Margin | -52.25% | -61.18% | -32.16% | -35.02% | -66.07% | Upgrade
|
| Profit Margin | -23.83% | -48.62% | -23.63% | -26.96% | -44.15% | Upgrade
|
| Free Cash Flow Margin | -22.09% | -78.70% | -4.05% | -12.25% | -35.82% | Upgrade
|
| EBITDA | -5.6 | -4.38 | -4.43 | -5.35 | -6.88 | Upgrade
|
| EBITDA Margin | -51.19% | -59.47% | -31.24% | -34.08% | -64.81% | Upgrade
|
| D&A For EBITDA | 0.12 | 0.13 | 0.13 | 0.15 | 0.13 | Upgrade
|
| EBIT | -5.71 | -4.5 | -4.56 | -5.5 | -7.01 | Upgrade
|
| EBIT Margin | -52.25% | -61.18% | -32.16% | -35.02% | -66.07% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.